In order to generate a secure foundation to guage the effects of glutamatergic agents in clinical trials of men with FXS, we have demonstrated the value of simultaneous measurements of FMRP levels and mGluR5 expression in relevant brain regions. The gene discussed is FMR1; the disease is fragile X syndrome.